Early research (Phase 1)Study completedNCT02100852
What this trial is testing
TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)
Who this might be right for
Chronic Lymphocytic Leukemia
TG Therapeutics, Inc. 19